Europeans Mull PCSK9i Post-FOURIER Fallout on Clinical Practice

The first PCSK9-inhibitor outcomes data prompted European Atherosclerosis Society experts to bemoan the cost of PCSK9 inhibitors but also to suggest "there's no such thing anymore as too low cholesterol."